Penumbra - PEN Stock Forecast, Price & News

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Penumbra Price Performance

Shares of NYSE:PEN traded down $4.97 during midday trading on Tuesday, reaching $169.72. The company's stock had a trading volume of 251,432 shares, compared to its average volume of 302,478. The business's fifty day simple moving average is $135.13 and its 200-day simple moving average is $172.22. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.93 and a quick ratio of 2.90. Penumbra has a fifty-two week low of $114.86 and a fifty-two week high of $293.20. The company has a market capitalization of $6.43 billion, a P/E ratio of -326.38 and a beta of 0.73.

Penumbra (NYSE:PEN - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.07. The company had revenue of $208.30 million for the quarter, compared to the consensus estimate of $206.24 million. Penumbra had a positive return on equity of 0.97% and a negative net margin of 2.40%. The firm's quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.21 EPS. As a group, equities research analysts expect that Penumbra will post 0.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PEN shares. Deutsche Bank Aktiengesellschaft lowered their target price on Penumbra from $250.00 to $163.00 in a report on Thursday, July 21st. William Blair reissued an "outperform" rating on shares of Penumbra in a research report on Tuesday, May 3rd. Royal Bank of Canada initiated coverage on shares of Penumbra in a research report on Monday, July 18th. They issued an "outperform" rating and a $195.00 price target for the company. Wells Fargo & Company lowered their price objective on shares of Penumbra from $321.00 to $265.00 in a research report on Wednesday, May 4th. Finally, Truist Financial reduced their target price on Penumbra to $180.00 in a report on Friday, July 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Penumbra has a consensus rating of "Moderate Buy" and an average price target of $218.78.

Insider Buying and Selling

In related news, Director Thomas Wilder sold 248 shares of the stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $123.64, for a total transaction of $30,662.72. Following the completion of the transaction, the director now owns 462 shares in the company, valued at $57,121.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 451 shares of company stock valued at $57,968. Company insiders own 5.50% of the company's stock.